• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Reunion Neuroscience Inc.

    8/18/23 12:56:55 PM ET
    $REUN
    Medical/Nursing Services
    Health Care
    Get the next $REUN alert in real time by email
    15-12G 1 tm2324141d1_1512g.htm 15-12G

     

     

    UNITED STATES

     SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTION 13 AND 15(d) 

    OF THE SECURITIES EXCHANGE ACT OF 1934.

     

    Commission File Number: 001-40635

     

     

    Reunion Neuroscience Inc.

    (Exact name of registrant as specified in its charter)

     

     

    30 Duncan Street, Suite 400

    Toronto Ontario, Canada M5V 2C3

    (416) 617-6277

    (Address, including, zip code and telephone number, including area code, of registrant’s principal executive offices)

     

    Common Shares

    (Title of each class of securities covered by this Form)

     

    None

    (Title of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1) x
    Rule 12g-4(a)(2) ¨
    Rule 12h-3(b)(1)(i) x
    Rule 12h-3(b)(1)(ii) ¨
    Rule 15d-6 ¨
    Rule 15d-22(b) ¨

     

    Approximate number of holders of record as of the certification or notice date: 1.

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Reunion Neuroscience Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

     

        Reunion Neuroscience Inc.
           
    Date:  August 18, 2023 By: 

    /s/ Gregory Mayes

          Gregory Mayes
          President and Chief Executive Officer

     

     

    Get the next $REUN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REUN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $REUN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement

      TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions and MPM BioImpact ("MPM") are pleased to announce the completion of the previously announced plan of arrangement (the "Arrangement") effective today, whereby MPM acquired Reunion in an all-cash transaction valued at approximately US$13.1 million by way of a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act. Pursuant to the terms and conditions of a definitive arrangement agr

      8/1/23 9:03:29 AM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement

      TORONTO, July 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions is pleased to announce that, earlier today, the Ontario Superior Court of Justice (Commercial List) granted a final order approving the proposed arrangement (the "Arrangement") under Section 192 of the Canada Business Corporations Act, with affiliates of MPM BioImpact ("MPM"). As previously announced, the Arrangement was approved by shareholders of the Company at its special meeting of shareholders held on July 12, 2

      7/14/23 4:05:00 PM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement

      TORONTO, July 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, is pleased to announce the voting results of the special meeting of shareholders of Reunion held yesterday, July 12, 2023 (the "Meeting"). At the Meeting, shareholders voted in favour of a special resolution (the "Arrangement Resolution") to approve the proposed plan of arrangement (the "Arrangement") under Section 192 of the Canada Business Corporations Act, whereby affiliates of MPM BioImpact would acquire Reu

      7/13/23 7:30:00 AM ET
      $REUN
      Medical/Nursing Services
      Health Care

    $REUN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Reunion Neuroscience Inc.

      15-12G - Reunion Neuroscience Inc. (0001865482) (Filer)

      8/18/23 12:56:55 PM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • SEC Form 6-K filed by Reunion Neuroscience Inc.

      6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

      8/1/23 10:54:08 AM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • SEC Form F-10POS filed by Reunion Neuroscience Inc.

      F-10POS - Reunion Neuroscience Inc. (0001865482) (Filer)

      8/1/23 9:53:09 AM ET
      $REUN
      Medical/Nursing Services
      Health Care

    $REUN
    Financials

    Live finance-specific insights

    See more
    • Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results

      Company Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and Tolerability with Differentiated Profile; Final Data Anticipated in Mid-2023 Continued to Strengthen Executive Team; Named Dr. Robert Alexander as Chief Medical Officer At December 31, 2022, Reunion Held CAD $32.4 Million in Cash and Cash Equivalents TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today provided a business update and re

      2/14/23 7:30:00 AM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

      TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that the Company plans to release its business update and financial results for Reunion's fiscal 2023 third quarter ended December 31, 2022, before market open on Tuesday, February 14, 2023. The Company will hold a conference call and webcast to discuss its results at 8:30 a.m. ET the same day. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conferen

      2/2/23 7:30:00 AM ET
      $REUN
      Medical/Nursing Services
      Health Care

    $REUN
    Leadership Updates

    Live Leadership Updates

    See more
    • Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors

      - Seasoned Psychiatrist and Global Pharmaceutical R&D Executive with Over Two Decades of Experience in Clinical Development, Including at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb and Sunovion Pharmaceuticals TORONTO, April 03, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has appointed psychiatrist Fred Grossman, D.O., FAPA, to its Board of Directors. Dr. Grossman has over two decades of experience in clinical development and medical affairs, ph

      4/3/23 7:30:00 AM ET
      $REUN
      Medical/Nursing Services
      Health Care

    $REUN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Reunion Neuroscience Inc. (Amendment)

      SC 13D/A - Reunion Neuroscience Inc. (0001865482) (Subject)

      8/1/23 10:53:55 AM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G filed by Reunion Neuroscience Inc.

      SC 13G - Reunion Neuroscience Inc. (0001865482) (Subject)

      6/20/23 4:06:16 PM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13D filed by Reunion Neuroscience Inc.

      SC 13D - Reunion Neuroscience Inc. (0001865482) (Subject)

      6/12/23 5:30:28 PM ET
      $REUN
      Medical/Nursing Services
      Health Care